- Home
- TPVG vs THRD Comparison
TPVG vs THRD Comparison
Compare TPVG & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- THRD
- Stock Information
- Founded
- TPVG 2013
- THRD 2019
- Country
- TPVG United States
- THRD United States
- Employees
- TPVG N/A
- THRD N/A
- Industry
- TPVG Other Consumer Services
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- TPVG Consumer Discretionary
- THRD Health Care
- Exchange
- TPVG Nasdaq
- THRD Nasdaq
- Market Cap
- TPVG 334.8M
- THRD 335.2M
- IPO Year
- TPVG N/A
- THRD 2022
- Fundamental
- Price
- TPVG $7.74
- THRD $6.00
- Analyst Decision
- TPVG Hold
- THRD Strong Buy
- Analyst Count
- TPVG 6
- THRD 3
- Target Price
- TPVG $7.63
- THRD $20.33
- AVG Volume (30 Days)
- TPVG 519.4K
- THRD 248.2K
- Earning Date
- TPVG 03-05-2025
- THRD 11-07-2024
- Dividend Yield
- TPVG 15.61%
- THRD N/A
- EPS Growth
- TPVG N/A
- THRD N/A
- EPS
- TPVG 0.27
- THRD N/A
- Revenue
- TPVG $115,271,000.00
- THRD N/A
- Revenue This Year
- TPVG N/A
- THRD N/A
- Revenue Next Year
- TPVG N/A
- THRD N/A
- P/E Ratio
- TPVG $28.33
- THRD N/A
- Revenue Growth
- TPVG N/A
- THRD N/A
- 52 Week Low
- TPVG $6.44
- THRD $5.60
- 52 Week High
- TPVG $11.58
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- TPVG 55.59
- THRD 23.75
- Support Level
- TPVG $7.51
- THRD $5.60
- Resistance Level
- TPVG $7.75
- THRD $11.78
- Average True Range (ATR)
- TPVG 0.18
- THRD 0.89
- MACD
- TPVG 0.04
- THRD -0.43
- Stochastic Oscillator
- TPVG 87.10
- THRD 6.50
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.